BioTech
How Pfizer ended up passing on my GLP-1 work back in the early ’90s
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class of drugs. But the
Jeffrey Flier
September 9, 2024